Introduction
Since the discovery of interferon (IFN) in 1957 (Isaacs & Lindenmann, 1957) , much evidence has been given on its involvement in the pathogenesis of and recovery from viral diseases, which strongly supports its use as an in vivo antiviral agent in man. Until recently, however, all studies showing a clear beneficial effect of endogenous or exogenous IFN in experimentally induced viral diseases were performed in a limited set of laboratory animal species. Extending the study of the IFN system to other species such as domestic animals should provide further information about its role in other viral disease models. With the help of the recent advent of recombinant DNA technology, IFN could also represent a new therapeutic agent with a broad antiviral spectrum and immunomodulatory properties in veterinary medicine, as recently shown in cattle (see Bielefeldt Ohmann et al., 1987 , for a review).
The pig represents an economically important animal species for food and hence the development of such a new therapeutic and/or prophylactic agent against infectious diseases in this species is strongly desirable. Moreover, the pig is an interesting model for investigating the role of endogenous IFN in viral infections and for studying the pharmacology and toxicology of exogenous homologous IFN (La Bonnardi6re et al., 1984) . Recently we showed that, as in the human, bovine and equine species (Capon et al., 1985; Hauptmann & Swetly, 1985; Velan et al., 1985; Himmler et al., 1986) , the porcine IFN-~ (PoIFN-~) multigene family can be divided into two homologous, but distinct classes of genes. The class I subfamily, located on porcine chromosome 1 (Yerle et al., 1986) contains at least 11 loci, of which nine have been cloned and two sequenced: PoIFN-~I and PoIFN-~2 (Lef6vre & La Bonnardi6re, 1986; F. Lef+vre, unpublished results) . The class II subfamily, which appears to be tightly linked to the class I subfamily, contains at least six distinct loci (F. Lef6vre, unpublished results). The low level expression of the PoIFN-~I gene in Escherichia coli revealed that its potential product, a preprotein of 189 amino acids with a putative N-terminal signal peptide of 23 amino acids, had an IFN-~ biological activity (Lef6vre & La Bonnardi6re, 1986) .
in this article, we describe the construction of plasmids allowing the intracellular synthesis of large amounts of mature porcine recombinant IFN-~I (rIFN-~1) in E. coli cells, its subsequent purification to homogeneity and some of its in vitro biological properties. (Grossman et al., 1983) transformed with the appropriate expression vector and grown in the enriched medium described by Mott et al. (1985) containing 3-2~ bactotryptone, 2~ yeast extract, 0.5~ Na2HPO4, 0.3% KH2PO4, 0.1% NH,,C1, 0-05% NaC1, 0.1 mMMgSO4, 0.001 mM-FeC13 in the presence of ampicillin (100 to 150 ~tg/ml).
DNA manipulation, plasmid constructions and nucleotide sequence analysis. All enzymes were used according to the manufacturer's recommendations. Oligonucleotides were synthesized on a Biosearch 8600 DNA synthesizer and purified further as described (Sambrook et al., 1989) . DNA manipulations and plasmid constructions were done according to standard procedures (Sambrook et al., 1989) and are summarized in Fig. 1 . Plasmid pD1A9225 (generously provided by Dr Antoine Danchin, Institut Pasteur, Paris, France) was the basic vector used for porcine 1FN-cd expression. It allowed thermoinducible expression of heterologous coding sequences fused to the C terminus of a cr~fl-galactosidase peptide (cr~flgal', 49 amino acids) (Leplatois & Danchin, 1983) . Plasmid pD1APoIFN-cd was constructed by inserting, at the unique PvuII site of pD1 A9225, the PvuII-Hpal fragment of the PoIFN-cd gene (containing sequences encoding part of the signal peptide and the complete mature protein) in the orientation allowing in-frame fusion with the cro-flgal' coding sequence. Plasmid pLD67 was constructed by cloning in the proper orientation (Lathe et al., 1984) a 49 bp synthetic blunt-ended DNA fragment at the PvulI site of pD1A9225. Due to this insert, translation of the cro-flgal' sequence stopped at an in-frame TAA codon which was followed, 13bp downstream, by the consensus Shine-Dalgarno sequence 5' AAG-GAGGT 3' (Gold, 1988) leading to a translational (re)initiation at a coding region inserted in the neighbouring unique XbaI site. Oligonucleotide-directed mutagenesis in bacteriophage M 13 (Zoller & Smith, 1982) was used to construct a gene encoding methionyl IFN-~I (MetIFN-~I): the sequence 5' CATATG 3' containing a methionine initiator codon and a unique NdeI restriction site was introduced just before the first codon (TGT, cysteine) of the putative mature IFN-cd coding sequence. Plasmid pLD67MetIFN-~l was constructed by inserting the MetIFN-cd coding sequence between the XbaI and SalI sites of pLD67 as described in Fig. 1 . The nucleotide sequence extending between the cro-flgal' and MetlFN-~I coding regions was controlled according to Chen & Seeburg (1985) using a synthetic DNA primer.
Monoclonal antibodies (MAbs).
A peptide corresponding to the 15 Cterminal residues of PolFN-cd (Lef6vre & La Bonnardi~re, 1986 ) was synthesized by the method of Merrifield using the Fmoc-polyamide mode (Atherton & Sheppard, 1985) and coupled to ovalbumin via glutaraldehyde. Fifty ~tg of conjugate was injected twice into 3 month old BALB/c mice with a 20 day interval. Boosted splenocytes were fused with selectable murine SP2/O myeloma cells and hybridomas were selected in medium containing azaserine (Galfre & Milstein, 1981) . Hybridomas were screened using a direct ELISA in plastic plates coated with the conjugate. Five MAbs which recognized both the synthetic peptide and the denatured form of rlFN-~I (not shown) were isolated. One of them, C8-18, was used for immunoblotting experiments. Other MAbs were prepared against the complete rlFN-~I molecule. Two month old BALB/c mice were immunized over a 130 day period by four injections of porcine IFN [105 international units (IU), half intraperitoneal and half intravenous] one of which consisted of porcine leukocyte IFN (PolFN-Le) and the others of the crude rIFN-cd preparation described below. Fusion between splenocytes and SP2/O cells was performed 4 days after the last injection, and growing hybridomas were screened for IFN reactivity by an immunosorbent bioassay set up in our laboratory (R. L'Haridon et.aL, unpublished results). Eight independent anti-IFN-c~ MAbs were isolated; one of them, C22, was used for the immunoaffinity purification of rIFN-cd.
Purification of rIFN-cG. E. coli strain CAGlI39 harbouring the plasmid pLD67MetlFN-cdAHS was grown overnight at 37 °C in enriched medium to an optical density at 600 nm (OD6o0) of about 5. Extraction of rlFN-ctl from the bacterial pellet was conducted essentially as described by Valenzuela et al. (1985) . The crude soluble extract was dialysed extensively against phosphate-buffered saline containing 0.02mM-PMSF, and rlFN-ctl was purified from this dialysate by a single-step immunoaffinity using specific anti-porcine rlFN-ctl MAb C22: monoclonal IgG was coupled to glutaraldehydeactivated amino-hexyl-Sepharose (Pharmacia) according to Cambiaso et al. (1975) . Bound IFN was eluted from the column with 0.1 M-acetic acid, 0.3 M-NaC1, pH 2.5, extensively dialysed as above and analysed by SDS-PAGE and reverse-phase HPLC. About 200 pmol of protein was subjected to N-terminal amino acid sequencing by sequential Edman degradation using a gas-phase Applied Biosystem 470A apparatus, equipped with on-line phenylthiohydantoin (PTH) amino acid analyser 120A.
Immunoblotting. Total bacterial proteins (0.5 OD600 unit of cell culture per gel slot) were separated by SDS-PAGE (Laemmli, 1970) followed by transfer to a nitrocellulose filter (Towbin et al., 1979) . Immunodetection of rlFN-~I was performed using a crude ascitic fluid containing MAb C8-18; the bound antibody was revealed using 35S-labelled Protein A (Amersham, 875 Ci/mmol, 100 gCi/ml) according to Burnette (1981) , and autoradiography of the filter.
IFN-ct antiviral assay and neutralization. E. coli cell extracts were prepared for an IFN-ct antiviral assay by resuspending the bacterial pellet from 1 ml of culture in 200 gl of TNE buffer (10 mM-Tris-HCl pH 8.0, 1 mM-EDTA, 100mM-NaC1), mixing the suspension with 200gl of lysis solution (10M-urea, 2% w/v SDS, 2% v/v 2-mercaptoethanol) and heating the lysate for 1 min at 100 °C. The IFN antiviral activity was assayed by inhibition of the c.p.e, of vesicular stomatitis virus on MDBK or other cell lines, as previously described (La Bonnardi6re & Laude, 1981) . Antiviral titres were expressed in IU by comparison with the international human IFN-Le (HulFN-Le) reference Ga23-902-530 (NIH, Bethesda, Md., U.S.A.). Neutralization of IFN antiviral activity was performed with a sheep anti-human IFNct serum using a previously described constant antibody method (La Bonnardidre et al., 1986) .
Results

High level expression of porcine rlFN-~I in E. coli cells
To test its ability for being expressed at a high level in E. coli, the PoIFN-~I coding sequence was inserted into the fused protein expression plasmid pD1A9225. The plasmid obtained, termed pD 1APolFN-~I, potentially codes for a 224 amino acid hybrid protein consisting of the entire mature IFN-~I and remaining nine amino acids of the signal peptide (S15 to $23) fused at the N terminus to the 49 residues of cro-flgal'. The pD1APolFN-~I construct was examined for protein synthesis in the protease-deficient strain (lon-) E. coli CAG 1139. Large amounts of a protein species with the expected Mr (28K) was detected by SDS-PAGE of total E. coli proteins after heat induction (Fig. 2a) . Western blot analysis of the gel showed that a band of similar size was the major protein species immunoreactive with the MAb C8-18 (Fig. 2b) .
As the aim of this work was to obtain a recombinant mature PolFN-cd devoid of its signal peptide, we chose to express the MetlFN-~I protein (mature IFN-~I with an additional N-terminal methionine) in E. coli. As pD1A9225 seemed to express the PolFN-~I coding sequence efficiently, we modified it to obtain pLD67 which permitted the expression of unfused coding sequences. The sequence encoding MetlFN-~I was constructed by site-directed mutagenesis of the prelFN-~1 coding sequence and inserted into pLD67. The plasmid obtained, pLD67MetlFN-~l, enabled the expression of a cro-flgal' peptide (of 51 residues) and MetIFN-~I from a bicistronic mRNA molecule. E. coli CAG1139 cells bearing this construct grown and heatinduced as described in Fig. 2 (c) contained a high antiviral activity (1.2 x 10 s IU/ml of bacterial culture on MDBK cells). In order to obtain constitutive expression of the recombinant protein, the HindIII-SmaI fragment bearing the Y end of the ci857 thermosensitive repressor gene was deleted from pLD67MetIFN-el (Fig. 1) . A saturation culture of E. coli CAG1139 harbouring this new construction (pLD67MetIFN-cdAHS) contained at least three times more antiviral activity (4 x 10 s IU/ml of bacterial culture on MDBK cells) than the previous one. Western blot analysis performed for both constructs revealed that a single protein species with an apparent Mr of 17.5K comigrating with IFN-c~ antiviral activity and corresponding to mature porcine rIFN-cd was immunodetected in E. coli cell extracts by the C8-18 MAb (Fig. 2c) .
Purification and N-term&at sequencing of mature porcine rlFN-cd
Biologically active rlFN-cd was extracted and purified as described in Methods. SDS-PAGE analysis revealed a single band with an Mr of 17"5K after Coomassie blue staining (Fig. 2d) . At this stage, specific activity of the purified rlFN-el ranged around 5 x 107 IU per mg of protein on MDBK cells. N-terminal sequencing confirmed that the recombinant IFN was the mature form. As the protein 
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subjected to the Edman degradation was not reduced or alkylated, the first N-terminal cysteine residue did not give a PTH derivative. We thus obtained: none-D-L-P-Q-T-H-S-L-A in the first 10 steps which clearly corresponds to the terminal sequence deduced from the D N A (Lef~vre & La Bonnardi6re, 1986) . On account of the yield of the first step of the Edman degradation (our result was 27~), which was within the normal range of yields (20 to 50~), and as no methionine-PTH was found, we think that at least a major fraction of rIFN-cd was non-methionylated and unblocked at its N terminus; however we cannot exclude the existence of a minor fraction, methionylated and blocked at its N terminus.
In vitro biological properties of rlFN-aI (i) Antiviral effect on different cells
The antiviral spectrum of rIFN-~I was compared with that of PoIFN-Le obtained by infection of pig peripheral blood lymphocytes with influenza virus (La Bonnardi6re et al., 1986) . For that purpose, we used a panel of five cell lines belonging to four different species (Table l) . It appeared that, like IFN-Le, rIFN-al exhibited a broad spectrum of antiviral activity (10~ activity on mouse cells as compared to MDBK cells). But interestingly, rlFN-~I was clearly more active (by sixfold) than its natural counterpart on homologous porcine cells. This Bovine  MDBK  3000  3000  Human  WISH  330  330  Murine  L929  440  250  Porcine  PD5  330  2200  ST83 110 660
* The antiviral titres of porcine IFN-Le and rlFN-c~l preparations having the same titre on MDBK cells (3000 IU/ml) were determined also on human, murine and porcine cell lines. * Confluent monolayers of MDBK or RPa 5495 cells were treated as for the antiviral assay with the same preparations of PolFN-Le, rlFNcd or HulFN-Le. Antiviral activity (AVA) of these preparations was expressed as log 3 of the highest dilution giving > 50~ protection of the cell sheet against virus challenge. Cytocidal activity (CCA) was expressed as the log 3 of the highest dilution at which cell sheets were 100~ killed (see Laude & La Bonnardi~re, 1984, for details) .
l" Sheep anti-human IFN-cc serum diluted 100-fold in the titration medium.
suggests that IFN-~I could not be a major component, if any, of the virus-induced IFN-Le.
(ii) Cytocidal effect It has been shown that IFNs from several species exert a toxic effect on primary cultures of pig kidney epithelial cells (Laude & La Bonnardi+re, 1984) . This so far unexplained phenomenon was observed specifically in porcine kidney cells, and only in primary or low-passage cells. We assayed rlFN-cd on these cells by comparison with both PolFN-Le and HulFN-Le (Table 2) . Clearly, the recombinant IFN-~ was cytotoxic for low-passage pig kidney cells. This effect was caused by IFN itself because in this assay we used rlFN-~I purified to homogeneity by immunoaffinity; also, the cytocidal as well as the antiviral effect were abolished by anti-IFN-e neutralizing antibodies. The ratio of antiviral to cytocidal titres for the three kinds of IFNs were similar and ranged around 33, which means that 30 antiviral units were enough to cause cell death in this system (Table 2 ).
(iii) Antigenicity It was of interest to determine whether rlFN-el shared antigenic determinants with PolFN-Le. Previous work showed that anti-human IFN-~ serum could neutralize PolFN-Le efficiently (La Bonnardi6re et al., 1986) . It appeared_ that this serum neutralized rlFN-~I to the. same extent (Table 3) . Recent results obtained with MAbs directed against rlFN-el confirm this high antigenic similarity between the cloned species and natural IFN (R. L'Haridon & C. La Bonnardi6re, unpublished results).
Discussion
A system for large-scale production of purified mature recombinant porcine IFN-~ was described. Quantitative optimization of this system is now in progress. However, the amount of recombinant protein already obtained is suitable for in vivo studies. The use of recombinant IFNs and other cytokines as immunomodulating and antiinfectious agents in domestic animals represents a growing field of interest. We have examined several in vitro biological properties of rlFN-~I and found several reasons for its suitability as a molecule for in vivo experimentation. Recombinant IFN-~I induced an efficient antiviral state in a panel of different cells. Moreover, it was at least six times more efficient than crude preparations of IFNLe in triggering this state on porcine cells. This could be because the IFN-~I subtype is less represented and exhibits a greater specific activity than other subtypes present in IFN-Le. Differences in the specific activities of IFN-ct subtypes have been well documented in other species: for example, recombinant human IFN-ct2 is 100 F. Lef~vre and others times more active than recombinant human IFn-cd in inducing an antiviral state in homologous human cells and this ratio is correlated with a different affinity for the IFN receptor (Streuli et al., 1981 ; Aguet et al., 1984; Uz6 et al., 1985) . Alternatively, as an N-glycosylation site is present at positions 78 to 80 of PoIFN-M (Lef~vre & La Bonnardi6re, 1986) , it cannot be excluded that it is normally expressed in IFN-Le and that the glycosylated leukocyte-derived protein has a lower antiviral specific activity than its recombinant unglycosylated E. coilderived homologue. According to Piasecky (1988) , PoIFN-Le would mostly be unglycosylated. If so, this finding argues in favour of IFN-M being a minor component of IFN-Le. In any case the fact that rIFN-cd is antigenically related to IFN-Le (Table 3) suggests that there are no major structural differences (in the active site of the molecule) between this IFN-c~ subspecies and those present in IFN-Le.
Amino acid sequencing revealed no methionine at the N-terminal end of rIFN-M. This is an advantage for in vivo use of the molecule because the presence of an additional methionine at the N termini of recombinant proteins might induce an immune response that could be deleterious to the host. Similarly, it was found by others that most human recombinant IFN-~2 molecules produced in E. coli are methionine-free at the N terminus (Nakagawa et al., 1987) . However in our study, the presence of a minor fraction of MetIFN-M formylated or blocked in another way cannot be excluded.
Previous work in our laboratory showed that various preparations of human, bovine and porcine IFN-Le could specifically induce a cytocidal effect in confluent monolayers of low-passage pig kidney epithelial cells (Laude & La Bonnardi+re, 1984) . The results presented here confirm these data and show that a recombinant porcine IFN-~ subspecies has retained this biological property. It was recently shown that recombinant murine IFN-7 exhibits a very similar effect on low-passage mouse embryonic fibroblasts (Dijkmans et al., 1989) . The ability of IFNs to induce active cell death in some normal tissues could represent a new property of these cytokines whose biological significance has not yet been established. The cytocidal effect could have serious implications for the toxicity of rIFN-cd and could prohibit its use for in vivo experiments, especially in the young animal. Clinical trials in man have clearly shown that recombinant IFNs can be responsible for some adverse reactions (Scott, 1983) . Besides, the work of G resser (1982) showed that large quantities of exogenous or endogenous IFN can induce toxic effects in newborn mice. However, preliminary data are now available to show that a single administration of rIFN-M did not induce any detectable toxic effect in newborn and adult pigs (C. La Bonnardi+re, unpublished results).
We believe that the availability of the porcine rIFN-cd molecule has opened a new field for in vivo investigations concerning the role of IFN in viral pathogenesis and its possible prophylactic use in pigs. During experimental infection of newborn pigs by the transmissible gastroenteritis coronavirus, which induces acute and often fatal diarrhoea, it has been shown that early after infection and before the onset of clinical signs, high levels of IFNare produced in the intestinal tract, lungs, serum and urine (La Bonnardi6re & Laude, 1981) . Recombinant IFN-M was used to obtain MAbs which can neutralize PoIFN-Le antiviral activity (R. L'Haridon et al., unpublished results). These antibodies could be used to investigate the pathogenic significance of this IFN-c~ response by neutralizing it during the course of infection. The possible anti-infectious and/or immunomodulatory properties of rIFn-M will be studied by examining its in vivo effects on the outcome of experimental virus diseases in pigs.
